 |
 |
|
|
| |
Novel
chemical diversity
Graffinity´s proprietary low molecular weight compound
libraries for chemical
microarrays are based on small drug fragments. The design principles
of these
collections allow insight into relevant structural features
early in the discovery
process and provide the basis for rapid optimization procedures.
Lead structures for your
targets
Graffinity uses its integrated discovery platform with unique
fragment based libraries, together with the Rapid Array Informed
Structure Evolution (RAISE) process, to take proteins from target
to novel lead. The combination of fragment based compound libraries
with Graffinitys low affinity screening technology establishes
a new route to novelty. Our collaborators provide the protein(s),
which we then test on our arrays to produce chemo-biological
data, and provide lead structures according to predefined biological
and/or chemical criteria.
Target prioritisation
approach for discovery on a genomic scale
Graffinity can provide chemical annotation of any number of
proteins. Working with many proteins in parallel per project
the fingerprint data can be used to prioritize targets for further
development in drug discovery and/or provide the basis of a
lead development program. Due to the array technology this approach
is very cost effective and fast.
Lead structures for orphan
targets & Early integration of chemistry and biology
As proteins can be screened against chemical microarrays prior
to their functional validation, the Graffinity approach delivers
the earliest possible chemical information on the potential
of small molecules as drug leads. |
|
|
|
|
|
| |
 |
|
RAISE
process delivers:
• Window to novel, diverse chemistry
• Fragments and low affinity binders
built
the basis for novelty
• Novel binding modes can be
characterized
early
• Fastest read on drug-ability of
targets
• Earliest look at SAR that is
technically
possible
• Scalable technology and process to
any
number of targets |
|
|
|
|
|
|
